EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CD34 positive cells as endothelial progenitor cells in biology and medicine

Mehdi Hassanpour, Amankeldi A Salybekov, Shuzo Kobayashi, Takayuki Asahara

Frontiers in Cell and Developmental Biology · 17.04.2023 · 11

DOI: 10.3389/fcell.2023.1128134 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 17.04.2023. Verfasst von Mehdi Hassanpour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34 + cells has attracted interest for application in patients with various vascular, ischemic, and inflammatory diseases. CD34 + cells have recently been reported to improve therapeutic angiogenesis in a variety of diseases. Mechanistically, CD34 + cells are involved in both direct incorporation into the expanding vasculature and paracrine activity through angiogenesis, anti-inflammatory, immunomodulatory, and anti-apoptosis/fibrosis roles, which support the developing microvasculature. Preclinical, pilot, and clinical trials have well documented a track record of safety, practicality, and validity of CD34 + cell therapy in various diseases. However, the clinical application of CD34 + cell therapy has triggered scientific debates and controversies in last decade. This review covers all preexisting scientific literature and prepares an overview of the comprehensive biology of CD34 + cells as well as the preclinical/clinical details of CD34 + cell therapy for regenerative medicine.

Schlagwörter

Stichwörter der Autor:innen

CD34 positive cellsendothelial progenitor cellsexosomeregenerative medicinevasculogenesis

Autor:innen und Institutionen

  • Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
  • Center for Cell Therapy and Regenerative Medicine, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
  • Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.

Zitieren

APA

Hassanpour, M., Salybekov, A. A., Kobayashi, S., & Asahara, T. (2023). CD34 positive cells as endothelial progenitor cells in biology and medicine. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1128134

Vancouver

Hassanpour M, Salybekov AA, Kobayashi S, Asahara T. CD34 positive cells as endothelial progenitor cells in biology and medicine. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1128134

BibTeX
@article{Hassanpour2023,
  author = {Hassanpour, Mehdi and Salybekov, Amankeldi A and Kobayashi, Shuzo and Asahara, Takayuki},
  title = {CD34 positive cells as endothelial progenitor cells in biology and medicine},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2023},
  volume = {11},
  doi = {10.3389/fcell.2023.1128134}
}
Kostenlos starten →